长期接受华法林治疗患者的凝血因子II、VII、IX和X浓度。
Factor II, VII, IX and X concentrations in patients receiving long term warfarin.
作者信息
Paul B, Oxley A, Brigham K, Cox T, Hamilton P J
出版信息
J Clin Pathol. 1987 Jan;40(1):94-8. doi: 10.1136/jcp.40.1.94.
Using standard one stage clotting assays the concentrations of factors II, VII, IX and X were determined in 37 patients stabilised on warfarin for between three months and 17 years. Contrary to popular belief, the concentrations were not equally depressed, with factor X the lowest, factor II at intermediate value, factors VII and IX the highest. Some 71% of the variance of the British corrected ratio (BCR) could be accounted for by measurement of the factors assayed. Analysis of this variance showed 91% of the explained variance attributable to factor II, 7% to factor VII, 1.6% to factor IX and 0.4% to factor X. With the sudden and recent withdrawal of human thromboplastin, investigation of the sensitivities of the animal thromboplastins to changes in vitamin K dependent factors in orally anticoagulated patients is needed to ensure that the potentially alarming falls in factors II and X in these patients are being adequately detected.
采用标准的一期凝血试验，测定了37例使用华法林稳定治疗3个月至17年患者的凝血因子II、VII、IX和X的浓度。与普遍看法相反，这些浓度并非同等程度降低，其中因子X最低，因子II处于中间值，因子VII和IX最高。通过测定所分析的凝血因子，可以解释约71%的英国校正比值（BCR）的方差。对该方差的分析表明，91%的可解释方差归因于因子II，7%归因于因子VII，1.6%归因于因子IX，0.4%归因于因子X。由于人凝血活酶近期突然停用，需要研究动物凝血活酶对口服抗凝患者维生素K依赖因子变化的敏感性，以确保能充分检测出这些患者中因子II和X可能出现的令人担忧的下降情况。
Zotero 插件